Breaking News Instant updates and real-time market news.

GMED

Globus Medical

$49.70

0.6 (1.22%)

16:19
05/15/18
05/15
16:19
05/15/18
16:19

Globus Medical announces results from study of expandable lateral spacers

Globus Medical announced the results of the study "Clinical and radiographic analysis of expandable versus static lateral lumbar interbody fusion devices with two-year follow-up" published in the Journal of Spine Surgery, supporting benefits of Globus' expandable lateral spacers. The study co-authored by Joseph O'Brien, orthopedic surgeon at Washington Spine and Scoliosis Institute and Richard Frisch, orthopedic surgeon at Southeastern Spine Institute, compared clinical and radiographic outcomes of fifty-six patients who underwent minimally invasive lateral lumber interbody fusion for symptomatic degenerative disc disease. At two-years post-operative, patients in both the expandable and static spacer groups reported similar improvements in back pain scores and no significant differences in clinical outcomes. Radiographic evidence confirmed solid fusion was achieved in 100% of levels treated in both groups, however, significant differences in the rate of implant subsidence were observed.

  • 25

    Jun

  • 26

    Jun

GMED Globus Medical
$49.70

0.6 (1.22%)

04/04/18
NEED
04/04/18
UPGRADE
NEED
Buy
Globus Medical upgraded to Buy from Hold at Needham
04/04/18
NEED
04/04/18
UPGRADE
Target $57
NEED
Buy
Globus Medical upgraded to Buy at Needham on trauma market entry and valuation
As reported earlier, Needham analyst Mike Matson upgraded Globus Medical (GMED) to Buy from Hold with a price target of $57. Matson cites the company's ExcelsiusGPS robot becoming more competitive with Mazor's (MZOR) Mazor X and the prospects for entry into the trauma market accelerating Globus Medical's growth. Moreover, Matson sees the stock as undervalued on the basis of his sum-of-parts analysis, stating that his price objective could be achieved in 2019.
04/16/18
BTIG
04/16/18
DOWNGRADE
BTIG
Neutral
Globus Medical downgraded to Neutral from Buy at BTIG
BTIG analyst Ryan Zimmerman downgraded Globus Medical to Neutral citing share strength over the past 12 months and views much of the good news as reflected in valuation.
04/17/18
PIPR
04/17/18
NO CHANGE
PIPR
J&J commentary positive for pure-play spine names, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien is out discussing derivative calls following Johnson & Johnson's (JNJ) Q1 results. The orthopedic market looked relatively stable, though Hips were notably softer than expected, O'Brien tells investors in a research note. He believes Stryker (SYK) is "clearly taking market share," which he views as an incremental negative for Zimmer Biomet (ZBH). On Spine, some U.S. weakness was expected, but J&J's results could be viewed as concerning given continued weakness since Q3 of 2017, the analyst adds. He thinks the end markets "are ok" and the commentary on J&J losing share benefits pure-play spine names NuVasive (NUVA), Globus Medical (GMED), SeaSpine (SPNE) and K2M Group (KTWO). He believes the pure-plays continue to out-innovate and take share despite the weakness in the overall category. Johnson & Johnson's results also show that the U.S. lens market remains strong and is shifting to 1-Days lenses from weeklies/monthlies, which is a positive for Cooper Companies (COO), O'Brien contends. Lastly, the analyst says the decline in J&J's U.S. diabetes franchise from the Animas exit was faster than expected. This is good for the pump names Insulet (PODD) and Tandem Diabetes (TNDM) and a slight negative for Dexcom (DXCM) as some of those will end up at Medtronic (MDT), O'Brien argues. He continues to believe that both Insulet and Tandem "will gain more than their fair share" of Animas patients.

TODAY'S FREE FLY STORIES

MLHR

Herman Miller

$37.30

0.2 (0.54%)

08:12
09/20/18
09/20
08:12
09/20/18
08:12
Technical Analysis
Technical Take: Herman Miller nears 52-week high after stronger results, outlook »

In pre-market trading the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

MANT

ManTech

$62.05

-2.62 (-4.05%)

08:09
09/20/18
09/20
08:09
09/20/18
08:09
Hot Stocks
ManTech an awardee on $28B AFICA contract »

ManTech announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPRT

Copart

$55.59

-8.59 (-13.38%)

08:09
09/20/18
09/20
08:09
09/20/18
08:09
Recommendations
Copart analyst commentary  »

Copart price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$43.27

-0.25 (-0.57%)

08:06
09/20/18
09/20
08:06
09/20/18
08:06
Hot Stocks
Pfizer granted FDA Breakthrough Therapy designation for 20vPnC »

Pfizer announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 01

    Oct

  • 10

    Oct

  • 17

    Oct

  • 22

    Oct

  • 30

    Oct

HCA

HCA Healthcare

$131.92

-1.86 (-1.39%)

08:06
09/20/18
09/20
08:06
09/20/18
08:06
Recommendations
HCA Healthcare analyst commentary  »

HCA Healthcare price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMED

OncoMed

$2.82

-0.07 (-2.42%)

, CELG

Celgene

$87.39

-0.22 (-0.25%)

08:06
09/20/18
09/20
08:06
09/20/18
08:06
Hot Stocks
Celgene will not exercise option to license OncoMed's navicixizumab »

OncoMed (OMED) announced…

OMED

OncoMed

$2.82

-0.07 (-2.42%)

CELG

Celgene

$87.39

-0.22 (-0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 29

    Oct

MO

Altria Group

$61.83

-0.31 (-0.50%)

, BTI

British American Tobacco

$46.87

-0.475 (-1.00%)

08:05
09/20/18
09/20
08:05
09/20/18
08:05
Recommendations
Altria Group, British American Tobacco, Philip Morris analyst commentary  »

Tobacco stocks to rally…

MO

Altria Group

$61.83

-0.31 (-0.50%)

BTI

British American Tobacco

$46.87

-0.475 (-1.00%)

PM

Philip Morris

$80.92

0.59 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 28

    Sep

SNHY

Helios Technologies

$55.00

0.49 (0.90%)

08:05
09/20/18
09/20
08:05
09/20/18
08:05
Upgrade
Helios Technologies rating change  »

Helios Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

ZG

Zillow

$43.78

-0.37 (-0.84%)

, Z

Zillow

$44.12

-0.49 (-1.10%)

08:04
09/20/18
09/20
08:04
09/20/18
08:04
Hot Stocks
Zillow signs listings agreement with Right at Home Realty »

Zillow announced that…

ZG

Zillow

$43.78

-0.37 (-0.84%)

Z

Zillow

$44.12

-0.49 (-1.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

GIB

CGI Group

$66.11

(0.00%)

08:04
09/20/18
09/20
08:04
09/20/18
08:04
Hot Stocks
CGI Group acquires ckc AG in Germany »

CGI announce its merger…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTW

Manitowoc

$24.50

0.8 (3.38%)

08:04
09/20/18
09/20
08:04
09/20/18
08:04
Upgrade
Manitowoc rating change  »

Manitowoc upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRKR

Bruker

$34.89

0.01 (0.03%)

08:03
09/20/18
09/20
08:03
09/20/18
08:03
Downgrade
Bruker rating change  »

Bruker downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

PSMT

PriceSmart

$83.60

-0.9 (-1.07%)

08:03
09/20/18
09/20
08:03
09/20/18
08:03
Hot Stocks
PriceSmart acquires land in Guatemala »

PriceSmart announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

WFC

Wells Fargo

$55.23

0.73 (1.34%)

08:01
09/20/18
09/20
08:01
09/20/18
08:01
Periodicals
Wells Fargo denies New York Post report on Cohn approach, CNBC says »

Wells Fargo is denying a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 21

    Oct

  • 12

    Apr

  • 13

    Jul

  • 15

    Oct

RHT

Red Hat

$143.38

0.59 (0.41%)

08:00
09/20/18
09/20
08:00
09/20/18
08:00
Recommendations
Red Hat analyst commentary  »

Red Hat price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$31.01

0.79 (2.61%)

08:00
09/20/18
09/20
08:00
09/20/18
08:00
Options
Bank of America call buyer realizes 319% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 23

    Sep

  • 25

    Sep

  • 27

    Sep

DRI

Darden

$117.90

-1.03 (-0.87%)

07:59
09/20/18
09/20
07:59
09/20/18
07:59
Technical Analysis
Technical Take: Darden hits new life high after results »

In the pre-market the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 11

    Oct

FBP

First BanCorp

$8.61

0.12 (1.41%)

07:59
09/20/18
09/20
07:59
09/20/18
07:59
Upgrade
First BanCorp rating change  »

First BanCorp upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 28

    Sep

  • 25

    Oct

XOMA

Xoma

$16.05

-0.15 (-0.93%)

07:58
09/20/18
09/20
07:58
09/20/18
07:58
Conference/Events
Xoma management to meet with Wedbush »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 01

    Oct

SQ

Square

$84.81

-3.16 (-3.59%)

07:58
09/20/18
09/20
07:58
09/20/18
07:58
Recommendations
Square analyst commentary  »

Square price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 26

    Sep

  • 26

    Nov

NWL

Newell Brands

$21.64

0.125 (0.58%)

07:57
09/20/18
09/20
07:57
09/20/18
07:57
Recommendations
Newell Brands analyst commentary  »

Wells sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WLH

William Lyon Homes

$18.64

-0.68 (-3.52%)

07:55
09/20/18
09/20
07:55
09/20/18
07:55
Downgrade
William Lyon Homes rating change  »

William Lyon Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPA

Copa Holdings

$80.01

0.595 (0.75%)

07:55
09/20/18
09/20
07:55
09/20/18
07:55
Conference/Events
Copa Holdings to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

WHLR

Wheeler REIT

$4.18

0.03 (0.72%)

07:54
09/20/18
09/20
07:54
09/20/18
07:54
Hot Stocks
Wheeler REIT reports minimal damage from Hurricane Florence »

Wheeler REIT announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAT

Caterpillar

$152.78

3.63 (2.43%)

07:54
09/20/18
09/20
07:54
09/20/18
07:54
Upgrade
Caterpillar rating change  »

Baird sees demand growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.